Valuation: Replimune Group, Inc.

Market Cap 2.08B 1.89B 1.74B 1.57B 2.97B 195B 3.07B 20.95B 8.3B 105B 7.79B 7.62B 331B P/E 2027 *
-9.49x
P/E 2028 * -19x
Enterprise Value 1.85B 1.68B 1.55B 1.4B 2.64B 173B 2.74B 18.64B 7.39B 93.06B 6.93B 6.78B 295B EV / Sales 2027 *
48.6x
EV / Sales 2028 * 8.13x
Free-Float
98.37%
Yield 2027 *
-
Yield 2028 * -
1 day-1.55%
1 week-3.14%
Current month+22.43%
1 month+98.53%
3 months+47.37%
6 months+330.34%
Current year+121.81%
1 week 20.48
Extreme 20.48
23.54
1 month 10.67
Extreme 10.67
23.54
Current year 1.5
Extreme 1.5
23.54
1 year 1.5
Extreme 1.5
23.54
3 years 1.5
Extreme 1.5
23.54
5 years 1.5
Extreme 1.5
35.93
10 years 1.5
Extreme 1.5
54.85
Manager TitleAgeSince
Chief Executive Officer 55 01/04/2024
Director of Finance/CFO 46 19/09/2023
Chief Tech/Sci/R&D Officer 60 01/12/2022
Director TitleAgeSince
Chairman 54 01/04/2024
Director/Board Member 66 01/07/2017
Chairman 65 01/04/2020
Date Insider Type Main position Quantity % Market Cap. Importance
11/2/26 A Exercice

Director

107,838 0.1145%
8/20/26 A Don

Founder

-50,000 0.0641%
8/17/26 A Sell

Chief Financial Officer

-9,256 0.0119%
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%-3.14%+145.84%+108.91% 2.08B
-1.29%-1.76%+51.98%+64.66% 66.33B
-0.09%+2.79%+10.75%+95.02% 60.62B
+0.63%+1.64%+24.25%+89.70% 55.5B
-0.98%-1.21%+9.46%+117.94% 47.58B
-0.03%-5.03%+22.53%+29.31% 43.69B
-2.98%-16.51%+141.70%+686.40% 37.27B
+0.23%+1.66%+14.85%+49.06% 36.57B
+2.35%-3.61%+78.64%+60.70% 32.22B
+1.50%+6.14%-37.57%+404.21% 26.58B
Average -0.21%+0.42%+46.24%+170.59% 41B
Weighted average by Cap. -0.22%+0.34%+35.60%+152.34%

Financials

2027 *2028 *
Net sales 38.01M 34.54M 31.91M 28.82M 54.39M 3.57B 56.31M 384M 152M 1.92B 143M 140M 6.07B 209M 190M 175M 158M 299M 19.61B 309M 2.11B 835M 10.52B 783M 767M 33.33B
Net income -233M -212M -196M -177M -334M -21.92B -346M -2.36B -934M -11.77B -876M -858M -37.27B -112M -102M -94.03M -84.94M -160M -10.52B -166M -1.13B -448M -5.64B -420M -411M -17.88B
Net Debt -228M -207M -192M -173M -327M -21.43B -338M -2.3B -913M -11.5B -856M -838M -36.43B -378M -344M -317M -287M -541M -35.51B -560M -3.82B -1.51B -19.05B -1.42B -1.39B -60.36B
Projected Income Statement - Annual - Replimune Group, Inc.
Logo Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Employees
465
Date Price Change Volume
16/11/26 $21.61 -1.28% 1,233,651
13/11/26 $21.89 -0.41% 2,020,798
12/11/26 $21.98 +0.92% 2,892,202
11/11/26 $21.78 -6.44% 3,031,865
10/11/26 $23.28 +4.58% 3,019,160
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Replimune Group, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
21.89USD
Average target price
25.50USD
Spread / Average Target
+16.49%
  1. Stock Market
  2. Stocks
  3. REPL Stock